INS and type 1 diabetes mellitus: In this observational study of patients with T1DM, the use of GLP-1RA, mostly semaglutide or liraglutide, as an add-on therapy to insulin resulted in a statistically significant reduction in HbA1c level, body weight, BMI, and basal insulin dose.